Growth Metrics

Boston Scientific (BSX) Gains from Investment Securities (2019 - 2026)

Boston Scientific's Gains from Investment Securities history spans 10 years, with the latest figure at -$30.0 million for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities fell 700.0% to -$30.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$119.0 million, a 158.7% decrease, with the full-year FY2025 number at -$84.0 million, down 1580.0% from a year prior.
  • Gains from Investment Securities hit -$30.0 million in Q1 2026 for Boston Scientific, up from -$95.0 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for BSX hit a ceiling of $89.0 million in Q4 2022 and a floor of -$95.0 million in Q4 2025.
  • Historically, Gains from Investment Securities has averaged $1.9 million across 5 years, with a median of $8.0 million in 2025.
  • Biggest five-year swings in Gains from Investment Securities: skyrocketed 545.0% in 2022 and later plummeted 700.0% in 2026.
  • Tracing BSX's Gains from Investment Securities over 5 years: stood at $89.0 million in 2022, then crashed by 83.15% to $15.0 million in 2023, then plummeted by 300.0% to -$30.0 million in 2024, then crashed by 216.67% to -$95.0 million in 2025, then soared by 68.42% to -$30.0 million in 2026.
  • Business Quant data shows Gains from Investment Securities for BSX at -$30.0 million in Q1 2026, -$95.0 million in Q4 2025, and $11.0 million in Q3 2025.